Top Markets
#1 Helium Helium +47.69%
#2 Pons Pons +37.87%
#3 TENDIES TENDIES +29.66%
#4 pipedog pipedog +22.25%
#5 Seeker Seeker +21.59%
#6 UnifAI Network UnifAI Network +19.17%
#7 Bounce Bounce +17.41%
#8 Songbird Songbird +12.58%
#9 Glidr Glidr +11.83%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +10.69%
Coin of the day
Helium Helium
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Classificação em ações #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Preço da ação
$9.50
Última sincronização: 2025-01-08
Valor de mercado
$819.52M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Poseida Therapeutics, Inc. (PSTX)

Categoria

Healthcare
Lucros da Poseida Therapeutics, Inc. (PSTX)
Lucros em Sep 2024 TTM: $-60.72M
De acordo com os últimos relatórios financeiros da Poseida Therapeutics, Inc., os ganhos atuais da empresa são de $-60.72M. Em 2022, a empresa teve ganhos de $-63.46M, uma diminuição em relação a aos ganhos de 2021, que foram de $-124.97K. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Poseida Therapeutics, Inc. de 2016 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
2026 (TTM) $-60.72M -50.77%
2023 $-123.32M 94.34%
2022 $-63.46M 50,676.96%
2021 $-124.97K -3.70%
2020 $-129.78K -99.85%
2019 $-86.53M 93.98%
2018 $-44.61M 120.94%
2017 $-20.19M 278.07%
2016 $-5.34M 0.00%
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -8,787.83%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -3,312.74%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 6,514.73%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 4,984.33%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH